Biomea Fusion (BMEA) investor relations material

Strategic focus and pipeline overview

• Focused on diabetes and obesity with two in-house developed assets, one a novel menin inhibitor and the other an improved GLP-1 agent.

• Funded through Q1 2027, enabling completion of current milestones without additional capital.

• Both assets target large, growing markets with differentiated mechanisms and patient-centric design.

Icovamenib (menin inhibitor) program insights

• Targets the root cause of diabetes by restoring beta cell mass and function, not just treating hyperglycemia.

• Preclinical and early clinical data show increased insulin production and improved glucose control, with effects persisting after treatment ends.

• Demonstrates synergy with GLP-1 therapies, especially in obese patients, and offers a non-chronic dosing regimen.

• Safety profile is favorable at 100mg, with mild to moderate liver enzyme elevations similar to placebo.

• Phase IIb studies are ongoing, with primary endpoints expected by year-end and potential for phase III advancement in 2025.

GLP-1 program and obesity pipeline

• Oral GLP-1 agent designed for improved patient adherence, longer half-life, and better bioavailability.

• Animal studies show promising weight reduction and reduced variability compared to competitors.

• Phase I trial underway, with data readout anticipated by end of Q2 2024.